Who makes Ibandronat?

Ibandronat is developed by GBG Forschungs GmbH.

What development phase is Ibandronat in?

Ibandronat is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Ibandronat

GBG Forschungs GmbH · FDA-approved active Small molecule Quality 0/100

Ibandronat, marketed by GBG Forschungs GmbH, is a well-established drug in its therapeutic class with a key composition patent expiring in 2028. Its primary strength lies in its long-standing market presence, which has solidified its reputation among healthcare providers and patients. The primary risk is the impending patent expiry, which could lead to increased competition from generic versions.

At a glance

Generic name	Ibandronat
Sponsor	GBG Forschungs GmbH
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ibandronat CI brief — competitive landscape report
Ibandronat updates RSS · CI watch RSS
GBG Forschungs GmbH portfolio CI